Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Solid Biosciences Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHARLESTOWN, MASS., JUNE 01, 2026 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED A GRANT OF 6,580 RESTRICTED STOCK UNITS (RSUS) TO ONE NEWLY HIRED EMPLOYEE.

SOLID BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

CHARLESTOWN, MASS., JUNE 01, 2026 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES: JEFFERIES GLOBAL HEALTHCARE CONFERENCE BO CUMBO, PRESIDENT AND CEO, WILL BE PRESENTING ON WEDNESDAY, JUNE 3, 2026, AT 7:35 A.M.

SOLID BIOSCIENCES TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES

- DUCHENNE (SGT-003): FIRST PARTICIPANT DOSED IN THE PHASE 3 IMPACT DUCHENNE CLINICAL TRIAL, RECEIPT OF POSITIVE OPINION ON THE COMPANY'S PEDIATRIC INVESTIGATION PLAN FROM THE EUROPEAN MEDICINES AGENCY AND ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION MARK IMPORTANT ADVANCEMENTS IN THE PROGRAM'S GLOBAL DEVELOPMENT -

SOLID BIOSCIENCES REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

- INITIATION OF PHASE 3 IMPACT DUCHENNE PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND TRIAL AS PART OF SOLID'S INTEGRATED, MULTI-TRIAL DEVELOPMENT PROGRAM DESIGNED TO SUPPORT REGISTRATION AND GLOBAL REGULATORY AUTHORIZATIONS FOR SGT-003 -

SOLID BIOSCIENCES DOSES FIRST PARTICIPANT IN PHASE 3 IMPACT DUCHENNE CLINICAL TRIAL EVALUATING SGT-003 IN DUCHENNE MUSCULAR DYSTROPHY

CHARLESTOWN, MASS., MAY 01, 2026 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED A GRANT OF 8,070 RESTRICTED STOCK UNITS (RSUS) TO ONE NEWLY HIRED EMPLOYEE.

- SOLID BIOSCIENCES DELIVERS ITS LARGEST SCIENTIFIC PROGRAM AT THE 2026 ASGCT ANNUAL MEETING WITH 5 ORAL PRESENTATIONS AND 11 POSTERS - CHARLESTOWN, MASS., APRIL 30, 2026 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED THAT MULTIPLE ABSTRACTS HAVE BEEN ACCEPTED FOR PRESENTATION AT THE UPCOMING 29TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT), TAKING PLACE MAY 11-15, 2026, IN BOSTON, MA.

SOLID BIOSCIENCES TO SHOWCASE A LARGE PRESENCE AT THE 29TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY

- ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION UNDERSCORES SOLID'S COMMITMENT TO ADVANCE SGT-003 THROUGH A GLOBAL DEVELOPMENT EFFORT FOR INDIVIDUALS LIVING WITH DUCHENNE MUSCULAR DYSTROPHY - CHARLESTOWN, MASS., APRIL 28, 2026 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC), ACTING UPON THE POSITIVE OPINION FROM THE EUROPEAN MEDICINES AGENCY COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS, HAS GRANTED ORPHAN DRUG DESIGNATION TO SGT-003 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DUCHENNE).

SOLID BIOSCIENCES ANNOUNCES RECEIPT OF EUROPEAN COMMISSION ORPHAN DRUG DESIGNATION FOR SGT-003 FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

CHARLESTOWN, MASS., APRIL 07, 2026 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY ANNOUNCED PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES: 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE BO CUMBO, PRESIDENT AND CEO, WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT ON TUESDAY, APRIL 14, 2026, AT 2:15 PM ET.

-DUCHENNE (SGT-003): POSITIVE INTERIM PHASE 1/2 INSPIRE DUCHENNE DATA REPORTED AT THE 2026 MDA ANNUAL MEETING CONTINUED TO SUGGEST DIFFERENTIATED CLINICAL, SAFETY AND TOLERABILITY PROFILES; SGT-003 HAS BEEN GENERALLY WELL TOLERATED IN THE 41 PARTICIPANTS DOSED AS OF MARCH 18, 2026 -

SOLID BIOSCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

- 40 PARTICIPANTS HAVE BEEN DOSED WITH SGT-003 IN THE INSPIRE DUCHENNE TRIAL TO DATE - - ROBUST MICRODYSTROPHIN EXPRESSION WITH CONSISTENT MECHANISTIC EVIDENCE OF DYSTROPHIN ASSOCIATED PROTEIN COMPLEX (DAPC) RESTORATION AND IMPROVEMENTS IN MUSCLE INTEGRITY, INCLUDING STABILIZATION AND IMPROVEMENT IN CARDIAC FUNCTION (LVEF) OBSERVED AFTER TREATMENT WITH SGT-003 - - SGT-003 CONTINUED TO DEMONSTRATE AN ENCOURAGING SAFETY PROFILE AND HAS BEEN GENERALLY WELL TOLERATED IN THE 40 PARTICIPANTS DOSED AS OF MARCH 11, 2026 - - SGT-003 IS ADMINISTERED USING A LOWER-BURDEN, STEROID-ONLY PROPHYLACTIC IMMUNOMODULATION REGIMEN - - THE COMPANY PLANS FOR ADDITIONAL MEETINGS WITH THE FDA IN H1 2026 FOR GUIDANCE ON A POTENTIAL ACCELERATED APPROVAL PATHWAY FOR SGT-003 AND EXPECTS TO PROVIDE AN UPDATE MID-2026 - CHARLESTOWN, MASS., MARCH 11, 2026 (GLOBE NEWSWIRE) -- SOLID BIOSCIENCES INC. (NASDAQ: SLDB) (THE COMPANY OR SOLID), A LIFE SCIENCES COMPANY DEVELOPING PRECISION GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC DISEASES, TODAY REPORTED UPDATED POSITIVE INTERIM DATA FROM THE ONGOING PHASE 1/2 INSPIRE DUCHENNE CLINICAL TRIAL OF SGT-003.

Solid Biosciences Inc.

SLDB

Price

Financial Reports

No items found.

Press Releases

Solid Biosciences Inc.

SLDB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SLDB